<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "http://www.fda.gov/cder/aerssub/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>170157_050</messagenumb>
		<messagesenderidentifier>NOVOPROD</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151547</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-NOVOPROD-369154</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>2</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20130115</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130116</receiptdate>
		<additionaldocument>1</additionaldocument>
		<documentlist>E2b Differences Report</documentlist>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>JP-NOVOPROD-369154</companynumb>
		<primarysource>
			<reportercountry>JP</reportercountry>
			<qualification>1</qualification>
			<studyname>#Trial Title:A multicentre, open label, observational, non-interventional study to evaluate on long-</studyname>
			<sponsorstudynumb>GH-3811</sponsorstudynumb>
			<observestudytype>3</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVOPROD</senderorganization>
			<senderdepartment>Product Safety and Clinical Quality Assurance</senderdepartment>
			<sendergivename>Novo</sendergivename>
			<sendermiddlename>Nordisk</sendermiddlename>
			<senderfamilyname>Inc.</senderfamilyname>
			<senderstreetaddress>100 College Road West</senderstreetaddress>
			<sendercity>Princeton</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>08540</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>6099875831</sendertel>
			<sendertelcountrycode>1</sendertelcountrycode>
			<senderfax>6099878480</senderfax>
			<senderfaxcountrycode>1</senderfaxcountrycode>
			<senderemailaddress>NNPI_AE_REPORTING@NOVONORDISK.COM</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDAEDI.CDER</receiverdepartment>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3018276504</receivertel>
			<receivertelcountrycode>1</receivertelcountrycode>
			<receiveremailaddress>WTaylor@OC.FDA.GOV</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientonsetage>65</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientagegroup>5</patientagegroup>
			<patientweight>52.6</patientweight>
			<patientheight>145</patientheight>
			<patientsex>2</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Growth hormone deficiency</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Craniopharyngioma</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>1995</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Tumour enlargement</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Tumour enlargement</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Neoplasm</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120613</reactionstartdate>
				<reactionfirsttime>512</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Norditropin FlexPro 10 mg/ml</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationnumb>21-148</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Novo Nordisk A/S</drugauthorizationholder>
				<drugstructuredosagenumb>.3</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>0.3 mg, qd</drugdosagetext>
				<drugdosageform>Solution for injection</drugdosageform>
				<drugadministrationroute>058</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Growth hormone deficiency</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20110118</drugstartdate>
				<drugstartperiod>512</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>SOMATROPIN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Neoplasm</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Unlikely</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Neoplasm</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Possible</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>DECADRON                           /00016001/</medicinalproduct>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Blood corticotrophin abnormal</drugindication>
				<activesubstance>
					<activesubstancename>DEXAMETHASONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>THYRADIN S</medicinalproduct>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Blood thyroid stimulating hormone decreased</drugindication>
				<activesubstance>
					<activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Study ID: GH-3811

Study description: A multicentre, open label, observational, non-interventional study to evaluate on long-term safety and efficacy of Norditropin formulation in patients with AGHD (Limited to Severe Conditions).

Phase: Observational

Patient ID: UNKNOWN

Centre ID: UNKNOWN

Patient's height: 145 cm.

This serious solicited case from Japan was reported by medical doctor as "tumor enlargement". It concerns a 65-year-old female patient treated with Norditropin FlexPro 10 mg/ml (somatropin) from 18-Jan-2011 and ongoing due to growth hormone deficiency.

Medical history includes growth hormone deficiency and craniopharyngioma.

The patient developed "tumour enlargement" on 13-JUN-2012. The patient reportedly received an imaging test (unspecified), which revealed that a small node on tuberculum sellae had been enlarged.

Action taken to Norditropin FlexPro was reported as no change.

The overall outcome of the events was reported as not yet recovered.

Reporter's causality: possible
Novo Nordisk's causality: unlikely

This case was upgarded to serious ("medically significant") on 16-JAN-2013 by Novo Nordisk.

Comment: company comment: Intracranial neoplasms often recur after a period of clinical remission. Treatment with growth hormone has not been shown to increase the risk of recurrence (1, 2). 

1. Jostel A, Mukherjee A, Hulse PA, Shalet SM. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol. 2005;62:698-705.  

2. Chung TT, Drake WM, Evanson J, Walker D, Plowman PN, Chew SL, Grossman AB, Besser GM, Monson JP. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. Clin Endocrinol. 2005;63:274-9.</narrativeincludeclinical>
				<sendercomment>Intracranial neoplasms often recur after a period of clinical remission. Treatment with growth hormone has not been shown to increase the risk of recurrence (1, 2). 

1. Jostel A, Mukherjee A, Hulse PA, Shalet SM. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol. 2005;62:698-705.  

2. Chung TT, Drake WM, Evanson J, Walker D, Plowman PN, Chew SL, Grossman AB, Besser GM, Monson JP. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. Clin Endocrinol. 2005;63:274-9.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
